Capricor Therapeutics, Inc. (CAPR) Stock Price & Analysis

Capricor Therapeutics, Inc. (CAPR) rose 1.29% to USD 9.4 as of September 8, 2026 at 07:36 UTC, according to Nexqual real-time market data.

CAPR last closed at USD 9.4; the session ranged USD 9.26–9.81 on volume of 2,555,651 shares. Market capitalization is —, with a 52-week range of USD 2.96–40.37 (NMS). Source: Nexqual, September 8, 2026 at 07:36 UTC.

Key Statistics (as of September 8, 2026 at 07:36 UTC)

Technical Analysis (CAPR)

Nexqual's technical model rates CAPR "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 07:36 UTC.

From Capricor Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)

Key Strengths & Strategy (as disclosed to the SEC)

• Biologics License Application : In late 2024, we completed our submission of a BLA to the FDA seeking approval of Deramiocel for the treatment of Duchenne muscular dystrophy.
• Following a Type A meeting with the FDA in August 2025, we aligned with the Agency on a regulatory path forward to address the CRL, including the submission of additional clinical data from the Phase 3 HOPE-3 trial.
• Exosome Platform: Engineered Exosome-Based Vaccines : The StealthX™ vaccine is a proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
• In mid-2025, the FDA completed its Pre-License Inspection ("PLI") of this facility in connection with our Biologics License Application for Deramiocel.

Partnerships

• In addition, Capricor may terminate for any reason upon 60 days' written notice. ​ Cedars-Sinai Medical Center License Agreements License Agreement for CDCs On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the "Original CSMC License Agreement"), for certain intellectual property related to its CDC technology.
• License Agreement for Exosomes On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the "Exosomes License Agreement"), for certain intellectual property rights related to CDC-derived exosomes technology.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:36 UTC. This page is informational and not investment advice.